Abstract
e21018 Background: anti-GD2 antibody, dinutuximab (Dmab), with GM-CSF or IL2, has significantly improved outcome in high-risk neuroblastoma (NB) in ANBL0032. Dmab generally induces cell lysis throu...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
